Catalent (NYSE:CTLT) had its price objective increased by equities researchers at Stephens from $65.00 to $75.00 in a research report issued on Monday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the stock. Stephens’ price target indicates a potential upside of 19.14% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday, January 14th. ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $60.57.
CTLT stock opened at $62.95 on Monday. Catalent has a 12 month low of $35.97 and a 12 month high of $63.22. The company has a current ratio of 2.06, a quick ratio of 1.65 and a debt-to-equity ratio of 1.73. The company has a 50-day moving average price of $57.22 and a 200 day moving average price of $53.26. The stock has a market cap of $9.01 billion, a PE ratio of 66.97, a P/E/G ratio of 2.66 and a beta of 1.69.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.07. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The firm had revenue of $664.70 million during the quarter, compared to analysts’ expectations of $634.87 million. During the same period in the previous year, the company earned $0.28 EPS. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. Sell-side analysts forecast that Catalent will post 1.78 EPS for the current year.
In related news, SVP Ricardo Pravda sold 2,612 shares of Catalent stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $52.73, for a total transaction of $137,730.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Aristippos Gennadios sold 45,256 shares of Catalent stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $52.55, for a total transaction of $2,378,202.80. The disclosure for this sale can be found here. Insiders have sold a total of 55,512 shares of company stock valued at $2,921,998 in the last quarter. 1.30% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in CTLT. Nuveen Asset Management LLC bought a new stake in shares of Catalent in the 2nd quarter valued at about $23,144,000. BlackRock Inc. raised its holdings in shares of Catalent by 2.8% in the 2nd quarter. BlackRock Inc. now owns 14,307,589 shares of the company’s stock valued at $775,615,000 after purchasing an additional 388,615 shares in the last quarter. GW&K Investment Management LLC raised its holdings in shares of Catalent by 13.3% in the 3rd quarter. GW&K Investment Management LLC now owns 2,010,273 shares of the company’s stock valued at $95,810,000 after purchasing an additional 235,371 shares in the last quarter. State of New Jersey Common Pension Fund D bought a new stake in shares of Catalent in the 3rd quarter valued at about $5,676,000. Finally, Fisher Asset Management LLC bought a new stake in shares of Catalent in the 3rd quarter valued at about $5,229,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Inverted Yield Curve
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.